2026年11月2日星期一
M
寰宇通鑑
全球快訊

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

來源 Nature 医学研究3 天前
內容摘要

This item is a 英文-language original; headline and summary shown as published.

本站僅提供標題與摘要索引,完整內容與版權均歸原發布方所有,請點擊原文連結閱讀。

前往原文
所屬頻道
健康
所屬地區
全球視角
原文語種
English
條目編號
health-a97f47b5

Comments 0 comments

No comments yet. Be the first.

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial · 寰宇通鑑